ARTICLE | Product Development
CEOs pledge rigorous Phase III testing for COVID-19 vaccines
O’Day: Gilead able to meet global demand for Veklury in real time beginning in October
September 4, 2020 1:30 AM UTC
As concerns grow around political pressure on FDA’s review process for COVID-19 countermeasures, a group of five biopharma CEOs reiterated Thursday that industry will not submit a COVID-19 vaccine or therapeutic for emergency use authorization or approval until randomized controlled trials clearly demonstrate their safety and efficacy.
The executives also delivered updates on their companies’ progress in developing COVID-19 countermeasures, with Gilead Sciences Inc. (NASDAQ:GILD) Chairman and CEO Daniel O’Day saying that the Bay Area biotech will be able to meet global demand for Veklury remdesivir beginning in October. ...